LifeMD's quarterly model allows for biomarker review and adjustment, whereas Ro's variable model depends on patient and prescriber initiative
In a landscape where cost and supply remain constrained, prescribing to cosmetic-use patients may displace access for patients with serious metabolic disease
Nothing changes except the price tag
Some insurers avoid covering GLP-1s due to high risks, while others only cover branded versions or exclude compounded forms not FDA-approved
Specialty pharmacies focus on dispensing and refill coordination
15 The statute defines minimal manipulation of HCTP products to mean (1) processing that does not alter the original relevant characteristics of the tissue relating to the tissues utility for reconstruction, repair, or replacement, and (2) for cells or non-structural tissues, processing that does not alter the relevant biological characteristics of cells or tissues